



11-03-05

IFW

Dkt. No. 96700/845

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : Ekaterina Dadachova, Joshua D. Nosanchuk, and  
Arturo Casadevall

Appl. No. : 10/775,869

Filed : February 10, 2004

For : RADIOLABELED ANTIBODIES FOR TREATMENT  
OF TUMORS

Group Art : 1642

Examiner : Brandon J. Fetterolf

Customer No. : 1912

"Express Mail" mailing label No. EL 993158391 US	
Date of Deposit: November 2, 2005	
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Name:	Alan D. Miller
Signature:	

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This Supplemental Information Disclosure Statement is being filed to  
supplement the Information Disclosure Statements filed on August 10, 2005 and on April  
16, 2004 in connection with the above-identified application.

In accordance with the duty of disclosure under 37 C.F.R. §1.56, applicants  
would like to direct the Examiner's attention to the two references that are both listed on  
enclosed Form PTO/SB/08B (1 page) and attached hereto.

Applicants: Ekaterina Dadachova, et al.  
Appl'n. No.: 10/775,869  
Filed: February 10, 2004  
Page 2


Applicants are submitting the subject Supplemental Information Disclosure Statement pursuant to 37 C.F.R. §1.97(b)(3) before the mailing of a first Office Action on the merits. Accordingly, no fee is deemed necessary in connection with the filing of this Supplemental Information Disclosure Statement. However, if any fee is required in connection with the submission of this Supplemental Information Disclosure Statement or to maintain the pendency of the subject application, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 01-1785.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN LLP  
Attorneys for Applicants  
90 Park Avenue  
New York, New York 10016  
(212) 836-8000

Dated: November 2, 2005  
New York, New York

By   
Alan D. Miller, Reg. No. 42,889



PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

<b>Sheet</b> 1 of 1	<b>Application Number</b>	10/775,869
	<b>Filing Date</b>	February 10, 2004
	<b>First Named Inventor</b>	Ekaterina Dadachova
	<b>Art Unit</b>	1642
	<b>Examiner Name</b>	Brandon J. Fetterolf
	<b>Attorney Docket Number</b>	96700/845

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	1	DADACHOVA, E ET AL., entitled "Melanin-targeting antibody as a potential agent for radioimmunotherapy of melanoma," World Journal of Nuclear Medicine, Volume 1, Supplement 2, September 2002, S275, Abstract.	
	2	DADACHOVA, E ET AL., entitled "Radioimmunotherapy of Pigmented Melanoma with Melanin-Targeting Antibody," In Program of Ninth Conference on Cancer Therapy with Antibodies and Immunoconjugates, October 2002, Abstract, P-08.	

<b>Examiner Signature</b>		<b>Date Considered</b>	
-------------------------------	--	----------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

**Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.